Shukui Qin News Today : Breaking News, Live Updates & Top Stories | Vimarsana

China Approves Imfinzi-Chemo Combo as First Immunotherapy for Advanced Biliary Cancer

China Approves Imfinzi-Chemo Combo as First Immunotherapy for Advanced Biliary Cancer
miragenews.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from miragenews.com Daily Mail and Mail on Sunday newspapers.

United kingdomSouth koreaUnited statesDave fredricksonShukui qinAstrazeneca imfinziDaiichi sankyoMerck co incChina national medical products administrationBiosciences incTianyinshan hospital of china pharmaceutical universityNational medical products administrationNew england journalMedicine evidenceNanjing tianyinshan hospitalChina pharmaceutical university

AstraZeneca : Imfinzi plus chemotherapy approved in China as first immunotherapy regimen for patients with locally advanced or metastatic biliary tract cancer -November 14, 2023 at 02:06 am EST

Approval based on results from TOPAZ-1 global Phase III trial and a Chinese patient cohort which showed a 22% reduction in the risk of death versus chemotherapy alone .

South koreaUnited kingdomUnited statesAstrazeneca imfinziDaiichi sankyoDave fredricksonShukui qinBiosciences incTianyinshan hospital of china pharmaceutical universityChina national medical products administrationMerck co incNational medical products administrationNew england journalMedicine evidenceNanjing tianyinshan hospitalChina pharmaceutical university

Durvalumab Plus Chemo Wins Approval in China For Advanced/Metastatic Biliary Tract Cancer

China’s National Medical Products Administration has approved durvalumab plus gemcitabine and cisplatin for frontline use in adult patients with locally advanced or metastatic biliary tract cancer.

United statesHong kongDave fredricksonShukui qinTianyinshan hospital of china pharmaceutical universityChina national medical products administrationNational medical products administrationNanjing tianyinshan hospitalChina pharmaceutical universityNorth americaSouth americaOncology business unitEuropean unionGlobal oncologyImmuno oncologyGastrointestinal cancer

Clinical trial of adjuvant therapy combination shows improved recurrence-free survival in liver cancer patients

Clinical trial of adjuvant therapy combination shows improved recurrence-free survival in liver cancer patients
medicalxpress.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from medicalxpress.com Daily Mail and Mail on Sunday newspapers.

Shukui qinOffice of researchNational cancer centre singaporeProfessor pierce chowSenior consultant surgeonSingapore general hospitalProfessor tan say bengGroup chief research officerSenior associate dean

The China NMPA Approved CYRAMZA® (ramucirumab) for the Treatment in Patients with Hepatocellular Carcinoma

/PRNewswire/ Innovent Biologics, Inc. ("Innovent", HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes.

United statesHong kongInnovent biologicsClin gastroenterolAdimab incyteYongjun liuPprofessor shukui qinEli lillyNational health commissionCancer centerMd anderson cancer centerLiver cancerNational medical products administrationInnovent biologics incIncyte corporationChinese society of clinical oncology